Follow by Email

Tuesday, November 15, 2011

Macklin Medical Mission - Stem Cells to Rebuild Hearts (Cancer Research)

Macklin Medical Mission
Cardiac Cells 'heal heart damage'

Stem cells taken from a patient's own heart have, for the first time, been used to repair damaged heart tissue similar to the use of Stem cells from bone marrow to form the basis of a cure for leukemia via white blood cells.
The study, published in the Lancet, in November of 2011 was designed to test the procedure's safety, but also reported improvements in the heart's ability to pump blood. The authors in both cases said the findings were "very encouraging" and are moving on to their second clinical trials.
Level of Improvement
The preliminary trial was on patients with heart failure who were having heart bypass surgery. During the operation, a piece of heart tissue, from the right atrial appendage, was taken.
While the patient was being sewn up, researchers isolated cardiac stem cells from the sample and cultured them until they had about two million stem cells for each patient. The cells were injected about 100 days later.
Doctors measured how efficiently the heart was pumping using the left ventricle ejection fraction - what percentage of blood was leaving one of the heart's main chamber with every beat.
“We believe these finding are very significant” Dr Roberto Bolli University of Louisville
In the 14 patients given the treatment in the first clinical trials, the percentage increased from 30.3% at the beginning of the trial, to 38.5% after four months.
There was no change in the ejection fraction in the seven patients who were not injected with their modified stem cells.
Dr Roberto Bolli, one of the researchers from the University of Louisville, told the BBC: "We believe these finding are very significant.
"Our results indicate that cardiac stem cells can markedly improve the contractile function of the heart."
Heart v Bone Marrow Stem Cells
The heart is not the only source of potentially useful stem cells. Trials have already taken place using stems cells from bone marrow.
Prof Anthony Mathur, from Barts and the London School of Medicine and Dentistry, and Prof John Martin, from University College London, are already conducting large randomised clinical trials.
They are investigating the effect of giving patients stem cells from their own bone marrow, in NHS hospitals, within six hours of a heart attack.
Prof Mathur said of the cardiac stem cell study: "Caveats very much apply. It's a phase one trial so while the early results are great and promising, they need to design a big study to see if the results translate."
He also cautioned that improvements in ejection fraction were not the same as increasing survival or quality of life.
Prof Martin said he was "concerned" that the seven patients in the control group showed no improvement in ejection fraction, which would normally be expected, and that they were not given a sham treatment to account for the placebo effect.
He said that was acceptable when just testing a procedure's safety, but not when looking at effectiveness, which relies on the difference between the treated and control groups.
Prof Peter Weissberg, medical director at the British Heart Foundation, argued that the improvement in heart function was similar to those in other studies.
"This is positive, but the crucial next steps are to see whether this improvement is confirmed in the final completed trial, and to understand whether the cells are actually replacing damaged heart cells or are secreting molecules that are helping to heal the heart," he added.
Dr Bolli argues that stem cells from the heart might be more useful as "their natural function is to replace the cells that continuously die in the heart due to wear and tear".
He plans to start the next phase of clinical trials in 2012.

This is similar in many ways to the use of Stem cells in cancer research which are used to modify or “translate” white blood cells, again taken from the patient, along with using the structural interface with other viruses such as those from the HIV virus which attack cellular structures in the body using the similar attack methods of cancer which “hitch” themselves to live cells. This “hitch interface” is then used to “translate” the body’s white blood cells and give them an “introduction to” the interface of cancer cells which they lacked up until April of 2011.

From here the “translated white blood cells” through the use of Stem cells now become a “naturalized” killer of cancer cells and cancerous tumours in the body. So far leukemia and leukomites and the tumours they create can now be destroyed without any damage to the body’s adjoining tissues. Recover time is now a fraction of what is with the use of the 75 year old chemically based treatments in chemotherapy and the nearly 135 year old use of x-ray based treatments called radiology from the mid 1880’s in all its varied forms.

We, at the Macklin Medical Mission, ask for your financial assistance to support our expanding efforts in this exciting new field of Stem Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.

We, at the Macklin Medical Mission, the oldest medical mission in the world, ask for your financial assistance to support our expanding efforts in this exciting new and highly successful field of white blood cells combined with T-Cell oncology research supported by the Nancy-Griffon Foundation Inc of Canada.
So, donate, support and invest in our cancer research – save a life.

Thank you.

Eric J. Macklin B.Com., FICB, FCSI, FMA, UE
Macklin Medical Mission [Est 1886]
Chairman
The Nancy-Griffon Foundation Inc [Est 1975]
Canada